Tiziana Life Sciences annual free cash flow
2017
2019
2020
2021
2024
Tiziana Life Sciences reported −$1.5M in free cash flow for fiscal 2024, an increase of $20.2M from the previous fiscal year.
View full Tiziana Life Sciences company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$1.5M | $20.2M | — | — |
| 2021 | 2021-12-31 | −$21.8M | −$10.4M | — | — |
| 2020 | 2020-12-31 | −$11.3M | −$4.5M | — | — |
| 2019 | 2019-12-31 | −$6.8M | $734,000 | — | — |
| 2017 | 2017-12-31 | −$7.5M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Tiziana Life Sciences filings at SEC.gov ↗